LDCA

CAS No. 349106-80-5

LDCA( —— )

Catalog No. M35413 CAS No. 349106-80-5

LDCA is a double-hit metabolic regulator that exhibits potent anti-proliferative activity. lDCA competitively inhibits LDH-A enzyme activity, alters mitochondrial hyperpolarization and simultaneously subverts apoptosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 39 In Stock
25MG 79 In Stock
50MG 128 In Stock
100MG 207 In Stock
200MG 295 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    LDCA
  • Note
    Research use only, not for human use.
  • Brief Description
    LDCA is a double-hit metabolic regulator that exhibits potent anti-proliferative activity. lDCA competitively inhibits LDH-A enzyme activity, alters mitochondrial hyperpolarization and simultaneously subverts apoptosis.
  • Description
    LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression.
  • In Vitro
    LDCA (2-100 μM; 16-72 h) is used in combination with doxorubicin synergistically, enhances the growth inhibition and induces mitochondria-mediated apoptosis by recruiting the caspase cascade, restricting migration, and obviating the clonogenic outgrowth potential of melanoma cells.Cell Viability Assay Cell Line:B16-F10 cells Concentration:2-100 μM Incubation Time:72 h Result:Arrested cell growth with a dose-dependent cytotoxic effect and had a strong synergism with LDCA.Apoptosis Analysis Cell Line:B16-F10 cells Concentration:20 μM Incubation Time:24 h Result:Resulted 15% death when cells exposed to LDCA and caused 40% melanoma cell death combination synergistically with doxorubicin.Immunofluorescence Cell Line:B16-F10 cells Concentration:20 μM Incubation Time:16 h Result:Demonstrated thatcombination with doxorubicin resultantly affected cellular morphologywith condensed and fragmented nuclei.Cell Migration Assay Cell Line:B16-F10 cells Concentration:20 μM Incubation Time:16 h Result:Signicantly limited the migratory potential in the B16-F10 cells.
  • In Vivo
    LDCA (2 mg/kg, iv., the 6th day, once) is used in combination with doxorubicin thwarts tumor growth kinetics to restrain oncogenic progression, thus accentuating survival in the model of murine melanoma.Animal Model:melanoma tumor model Dosage:2 mg/kg Administration:2 mg/kg, iv., the 6th day, once Result:Significantly increased mice survivability combination with doxorubicin, and relieved mice tumor necrosis phenomena.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis | Dehydrogenase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    349106-80-5
  • Formula Weight
    256.49
  • Molecular Formula
    C8H5Cl3FNO
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (389.88 mM; Ultrasonic (<60°C)
  • SMILES
    N(C(C(Cl)Cl)=O)C1=CC(Cl)=C(F)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Saha, Suchandrima, et al. The dual-hit metabolic modulator LDCA synergistically potentiates doxorubicin to selectively combat cancer-associated hallmarks. RSC Advances, 7(84), 53322–53333. doi:10.1039/c7ra08625c.
molnova catalog
related products
  • CTA 056

    CTA 056 is an interleukin-2 induced T cell kinase (ITK) inhibitor, inhibits the growth of MOLT-4 xenograft tumors in mice, induces apoptosis in Jurkat cells, and can be used in the study of autoimmune disorders and T cell malignancies.

  • AOH1996

    AOH1996 is an orally active ligand for the replicasome component PCNA (proliferating cell nuclear antigen), targeting the transcription-replication conflict (TRC).

  • SMIP004

    SMIP004 is an SKP2 E3 ligase inhibitor. SMIP004 is a cancer cell-selective apoptosis inducer of human prostate cancer cells.